Envy Adds Third Generation SilkPeel
Envy Medical has added the third generation of their SilkPeel system. The
third generation of the system is said to deliver a “state-of-the-art Dermalinfusion
treatment” via aClarityMD infusion (salicylic acid and solubized
bakuchiol) that is used for acneic skin and a Lumixyl peptide solution used
Unveiled in 2005, SilkPeel is celebrating its 10th anniversary in style with
fresh features, enhanced functionality and a sleek new design. During the
past decade, SilkPeel’s distribution has expanded to more than 40 countries,
with 3,000 systems in use worldwide.
SilkPeel3 is an advancement in ease-of-use, functionality, and efficacy,
contended the company. A SilkPeel3 Facial costs approximately $125-150, and is available at select spas, medical spas, and dermatologist
offices nationwide. It is sleeker, more compact, and has an innovative
"IndiviDUAL Infusion" dual-port design that loads two serum solutions
at once, allowing for more tailored treatments that address multiple
skin concerns. SilkPeel3 can treat blemishes, dry skin, dark spots, and a
host of other common skin concerns in one session.
Additional improvements include the ergonomically improved "Plexus"
hand piece with the option of new disposable medical-grade stainless steel
treatment tips that make the treatment more comfortable and effective by
eliminating incomplete passes and delivering more powerful and precise
pneumatic vacuum results.
The new SilkPeel3 offers an even wider treatment range, expanding the
system’s efficacy to multiple body applications as well.
Fotona’s Q-Switched Lasers for Advanced Pigment
Q-switched lasers have long been recognized as the gold standard technology
for removal of natural as well as man-made pigments (i.e. tattoo
inks) from skin tissue. Using selective photothermolysis and a unique
photoacoustic effect, Q-switched laser energy penetrates safely through
the epidermis to break apart specific pigments, allowing them to be easily
cleared from the body.
A multi-wavelength Q-switched system such as Fotona’s QX MAX, which
offers four treatment wavelengths in a single system (1064 nm Nd:YAG,
532 nm KTP, 650 nm dye, 585 nm dye), provides a complete selection of
wavelengths for treating pigmented and vascular lesions. For example, superficial
pigmented lesions can be treated most effectively with the 532 nm
wavelength, while the 1064 nm wavelength is optimal for targeting deeper
Laser wavelength must be considered when removing pigments, especially
with multi-colored tattoos. To ensure safe and effective treatments,
you’ll need an optimized selection of wavelengths to target a wide range
of pigments. Black and blue inks respond well to the QX MAX’s 1064 nm
wavelength, red and brown respond to its 532 nm wavelength, while
other colors such as green and sky blue can be more effectively treated
with the 650 nm and 585 nm wavelengths, respectively.
News from Solta
Solta Medical, a division of Valeant Pharmaceuticals North America LLC
announced the availability of the Clear + Brilliant pelo™ laser in the
United States, a sophisticated approach to permanent hair reduction.
The launch of this device, which joins the comprehensive portfolio of
Solta Medical's aesthetic device solutions, follows a unique partnership
with German Medical Engineering, (GME), a sophisticated leader in the
development of high-performance aesthetic energy devices.
The Clear + Brilliant pelo laser system uses a novel linear scanning approach
with integrated contact cooling to deliver the effectiveness of
current best-in-class diode laser hair removal technology with the fastest
and largest treatment area available (50mm by 15mm). In addition,
a unique all-inclusive subscription model will provide ease-of-mind and
simplicity in ensuring consistent device performance and dependable
ZELTIQ Receives FDA Clearance to Treat Submental
Fat With Coolsculpting Procedure
ZELTIQ® Aesthetics, Inc. announced that it received an expanded clearance
from the U.S. Food and Drug Administration, paving the way for
introduction of the new, CoolMini™ applicator, which is designed to treat
smaller pockets of fat, including the submental area. The applicator's size,
shape, and curvature is designed to comfortably fit these small, problem
areas. Patients may see results as early as 3 weeks, with the most dramatic
results generally observed 1-3 months following treatment.
The FDA clearance is based on data from a U.S. pivotal clinical trial involving 60
male and female patients, ranging in age from 22 to 65 years. In the trial, patients
received 1-2 treatments in the area under the chin, each six weeks apart, resulting
in an average of 20% fat reduction, which is in line with results achieved
with other CoolSculpting applicators. Additionally, no significant adverse events
were observed and patients experienced little to no discomfort or downtime.
CleoPen for Collagen Induction
The CleoPen (a division of RBELL Medical LLC) is set to break new
ground in regenerative medicine, particularly in the areas of scar treatment,
fine line and wrinkle reduction, and medical tattooing, among
other applications. The device represents the next step in the evolution
of collagen induction therapy, a proven technique for encouraging the
structural restoration of skin.
The CleoPen distinguishes itself in terms of its versatility and optimization
of well-researched, effective aesthetic procedures. The device also
allows practitioners to add platelet rich plasma (PRP) therapy to their
aesthetic procedure toolset; PRP is a recently developed approach that
uses the patient's own blood to synthesize an effective and safe dermal
LEO Pharma Inc. Announces FDA Approval of
Enstilar® for Plaque Psoriasis
LEO Pharma Inc announced that Enstilar® has been approved by the U.S.
Food and Drug Administration (FDA) for the topical treatment of plaque
psoriasis in adults 18 years of age and older.
Enstilar® is a once-daily, alcohol free foam formulation in a pressurized
spray can that allows application across large body areas of plaque
psoriasis. In the pivotal Phase 3 clinical trial, over half of patients treated
with Enstilar® were "Clear" or "Almost Clear" by week 4 as assessed
by the Investigator Global Assessment (IGA) score of disease severity.
Additionally, more than half of patients treated with Enstilar® achieved
a 75% improvement in Psoriasis Area and Severity Index (PASI) score
from baseline. Adverse reactions were reported in less than 1% of patients
treated and included application site irritation, application site
pruritus, folliculitis, skin hypopigmentation, hypercalcemia, urticaria,
and exacerabation of psoriasis.